Outpatient Oncology Infusion Market - By Product, By Application, By Therapy, By Mode - Global Forecast, 2026 - 2035

Outpatient Oncology Infusion Market Size

The global outpatient oncology infusion market was estimated at USD 2.9 billion in 2025. The market is expected to grow from USD 3.2 billion in 2026 to USD 8 billion in 2035, at a CAGR of 10.6% during the forecast period, according to the latest report published by Global Market Insights Inc.

The outpatient oncology infusion market is driven by the increasing preference for cost-effective outpatient care, rising prevalence of cancer, supportive government initiatives for cancer awareness, and technological advancements in infusion pumps, among other factors.
 

Growing adoption of targeted therapies and immunotherapies, a shift toward value-based care models, and increasing use of telehealth-assisted infusion care are among the key factors propelling the industry demand. Becton, Dickinson, and Company, Baxter, B. Braun, Fresenius Kabi, and ICU Medical are among the leading players operating in the market. These players mainly focus on geographic expansion, collaboration with local or regional healthcare providers, and innovation and integration of advanced technologies in devices, among others.
 

The market has increased from USD 2.2 billion in 2022 and reached USD 2.7 billion in 2024, with the historic growth rate of 10.5%. There is a significant rise in the development and adoption of outpatient oncology infusion services owing to the growing incidence of cancer globally. For instance, according to the 2022 GLOBOCAN report, more than 4.4 million new cancer cases were recorded in Europe. The same report highlighted that over 2.3 million were male patients and around 2.1 million were female patients in the region. In recent periods, the primary causes for the increase in cancer incidence include lifestyle choices, obesity and other disease burdens, and pollution or environmental factors. As more people develop cancer, patients require increased treatment options and better outcomes. The outpatient infusion model is expected to offer patients better efficiency and convenience when receiving their treatments (chemotherapy, immunotherapy, etc.) without the need for hospitalization. In addition, this model is anticipated to treat more patients and decrease total expenses associated with cancer treatment, therefore pushing the market growth.
 

In the last couple of years, outpatient oncology infusion has witnessed substantial improvement through the use of advanced infusion technology in smart infusion pumps, which offer automated dosing, error detection, and integration with EHRs (electronic health records). These innovations improve safety, reduce errors associated with medication administration, and increase precision of medication dosing for the patient receiving treatment. Portable/programmable infusion systems make it easier for patients to move around comfortably while receiving chemotherapy. Wireless technology is also a significant development for outpatient infusions because it allows real-time, on-demand monitoring of patients and facilitates remote support to patients in an outpatient setting. Thus, all these enhancements in technologies are expected to propel the product demand over the analysis period.
 

Governments across all the countries have a keen focus on increasing and promoting cancer-related awareness to aid in early detection and timely intervention. Funding for outpatient infrastructure to build the necessary systems and services for affordable care includes support for outpatient infusion centers and other programs that support patients in receiving timely treatment in an accessible environment. For example, the Indian Cancer Society, in collaboration with other entities, is working to raise cancer-related awareness among the Indian population through its campaign 'Raho Cancer Se Do Kadam Aage.' In addition, the government's continued commitment to increasing access, affordability, and quality of cancer care through policy support is projected to strengthen the outpatient model of cancer care delivery. As more governments prioritize preventive care, they are expected to drive demand for outpatient oncology infusion services globally.
 

Outpatient oncology infusion is the administration of cancer treatments such as chemotherapy, immunotherapy, or targeted therapy via intravenous infusion in a clinical setting without requiring an overnight hospital stay.
 

Outpatient Oncology Infusion Market Trends

A shift toward value-based care, growing use of targeted and immunotherapies, adoption of smart infusion pumps, and integration of digital health and remote monitoring are among the key trends fueling the industry growth.
 

• Automated dosing, error notification, and electronic health record connectivity are guiding smart pump development toward becoming a 'standard' delivery mechanism for outpatient infusion therapies. These latest innovations are making outpatient infusion therapy safer and more appealing to outpatient infusion providers and patients by improving the accuracy of treatments, reducing the risk of medical errors, and creating an efficient and streamlined workflow for outpatient infusion providers.
   
• In contrast to traditional fee-for-service models, which incentivize volume and quantity, modern value-based models emphasize the importance of cost and patient outcomes. Outpatient infusion centers achieve both of these goals by offering an alternative to hospitalization while providing greater patient convenience; thus, they play a key role in developing a more sustainable model for cancer care.
   
• In addition, infusion workflows are incorporating digital platforms and telehealth to improve overall outcomes. These tools provide clinicians with remote patient monitoring capabilities and enable them to assess patients’ adherence to therapies. This is important for enhancing patient safety and reducing repetitive office visits. Further, through the implementation of these tools, outpatient infusion environments are improving overall operational efficiency and providing patients with the best possible level of individualized care.
   
• Furthermore, advances in oncology treatments, such as immunotherapy and targeted drugs, require controlled infusion environments. As more outpatient infusion centers adopt these latest technologies and offer specialized protocols, it is expected to propel the market growth over the analysis period.
   

Outpatient Oncology Infusion Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

In 2022, the market was valued at USD 2.2 billion and grew to USD 2.4 billion in 2023, reaching USD 2.7 billion by 2024. Integration of telehealth and remote monitoring along with innovations in infusion pumps are among the key variables contributing to industry growth.
 

Based on product, the global market is segmented into infusion pumps, intravenous sets, IV cannulas, and needleless connectors. The infusion pumps segment accounted for a leading share of 50.2% in 2025. Technological advancements in infusion pumps and smart systems are anticipated to fuel the segmental growth. The segment is expected to reach USD 3.9 billion by 2035, growing at a CAGR of 10.3% during the forecast period.
 

• During chemotherapy, immunotherapy, and other cancer treatments, infusion pumps provide accurate and consistent dosing of these medications. Infusion pumps utilize intelligent technology to provide a high degree of automation (with programmable dosing), alerts for errors, and electronic health records (EHR) integration to increase workflow efficiency and patient safety.
   
• Infusion pumps offer an easy-to-use portable design and allow greater flexibility during infusion sessions, both enhancing patient experience and enhancing patient experience and supporting a more personalized approach to therapy.
   
• Thus, with advances in infusion pump technology, infusion pumps have become a primary component of outpatient oncology infusion services.
   
• The needleless connector segment was valued at USD 876.2 million in 2025. A needleless connector is a small, specialized device that provides secure access to intravenous (IV) lines without the use of traditional needles, thereby removing the risk of needlestick injury and transmission of bloodborne pathogens.
   
• Needleless connectors provide a closed system for the administration of medication and enhance safety for patients and healthcare workers by maintaining sterility and preventing contamination.
   
• Additionally, they allow for the administration of multiple medications via the same lines. The use of needleless connectors in outpatient oncology infusion centers is expected to improve infection control, simplify workflows and support global safety initiatives, thereby fueling the product demand.
   

Based on application, the global outpatient oncology infusion market is segmented into lung cancer, liver cancer, breast cancer, prostate cancer, and other cancers. The breast cancer segment accounted for a leading share and was valued at USD 599.6 million in 2025.
 

• One of the most prevalent forms of cancer around the world is breast cancer, which requires multiple infusion therapy methods, including chemotherapies, targeted therapies, and immunotherapies. For instance, as per the data reported by the Centers for Disease Control and Prevention (CDC), 279,731 new breast cancer cases were recorded in the U.S. in 2022.
   
• These types of therapies are conducted at outpatient infusion centers, which provide patients with greater convenience, reduced costs, and less stress on the hospital environment and the patient.
   
• Additionally, as breast cancer incidence rises and more personalized medicine solutions become available, there has been an increase in the need for outpatient infusion services that cater specifically to individualized treatment regimens.
   
• The prostate cancer segment held a revenue of USD 347.3 million in 2025, with projections indicating a steady expansion at 11.5% CAGR from 2026 to 2035. Many of the treatments for prostate cancer include either hormonal therapy or chemotherapy given at an infusion center.
   
• Infusion centers enable patients to receive treatment without spending extended periods in a hospital setting and consequently improve patients’ quality of life and ability to follow through with their treatment protocols.
   
• Further, the growing number of older patients diagnosed with prostate cancer and the increased utilization of advanced infusion technology have also contributed to the rapid growth of outpatient care as a viable alternative method for treating prostate cancer.
   
• The lung cancer segment is anticipated to record fastest growth with a CAGR of 11.7% over the forecast period. Patients with lung cancer generally receive various aggressive treatment options, such as infusion of chemotherapy and immune-modulating therapies, using outpatient centers that possess high-quality, modern equipment, such as modern infusion pumps and monitoring devices.
   
• With the increasing global burden of lung cancer and with new therapies developed to treat it being used increasingly on an outpatient basis, the need for outpatient infusion has rapidly increased, giving patients flexibility and supporting lower overall healthcare costs.
   

Based on therapy, the global outpatient oncology infusion market is segmented into chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. The targeted therapy segment accounted for a majority share of 39.5% in 2025.
 

• Targeted therapies are drugs that target specific molecular targets associated with cancer growth. Unlike traditional chemotherapy, which is more generalized, targeted therapies have the advantage of being more precise.
   
• Targeted therapies are often delivered via controlled infusion to achieve optimal outcomes; thus, outpatient infusion centers represent a preferred option for the delivery of these medications. The increasing utilization of targeted therapies is necessitating the development of advanced infusion technology and an increase in trained personnel for accurate infusion monitoring and dosing.
   
• Outpatient facilities allow for the convenience of access to treatment while simultaneously providing cost savings for patients as well as maintaining a high level of quality clinical care, which is supportive of the ongoing trend toward personalized treatment for cancer.
   
• The immunotherapy segment held a revenue of USD 1 billion in 2025. Immunotherapy uses the body's immune system to fight cancer, and it is becoming a more common form of treatment for many cancers due to its high success rate.
   
• Most immunotherapy treatments require complicated infusion methods with intensive patient monitoring to detect any adverse reactions or complications. Hence, these therapies are administered through outpatient infusion centers that have access to smart pump systems, which allow patients to be monitored in a safe, convenient manner without placing additional strain on the hospital system.
   
• As immunotherapy becomes a standard approach in cancer treatment, there has been an increased demand for outpatient facility accessibility, which is leading to a rise in investment prospects for outpatient infusion centers. These settings are being developed with specialized facilities and trained staff designed for administering immunotherapy.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on mode, the outpatient oncology infusion market is segmented into intramuscular (IM), intravenous (IV), subcutaneous, and other modes. The intravenous segment accounted for the leading market share of 32% in 2025.
 

• Oncology treatment (such as chemotherapy, immunotherapy, or targeted therapy) is predominantly delivered via intravenous (IV) administration, as this route allows for rapid delivery of drugs into the bloodstream with an accurately controlled rate of absorption. Outpatient infusion facilities' dependence on IV is primarily due to its highly precise method of drug administration, as well as the ability of IV to effectively manage difficult and complex treatment schedules.
   
• In addition, with the continued evolution of advanced infusion pump technology and enhanced monitoring systems that provide real-time information, the accuracy of drug delivery and have declined considerably since the adoption of these technologies.
   
• Additionally, with its continued integration into outpatient treatment methods and the increases in technological capabilities, IV therapy has become one of the go-to modes in oncology treatment.
   
• In addition, the intramuscular (IM) segment was valued at USD 642.8 million in 2025. Intramuscular (IM) administration refers to the process of injecting medications into deep muscle tissue, thereby providing a method for medications to be absorbed slowly into the bloodstream through muscle tissue. IM has primarily been used for supportive therapies, including antiemetics, analgesics, and hormone therapy, rather than as a method for delivering the primary chemotherapy treatment.
   
• Outpatient infusion sites prefer IM injections because they are relatively easy to use, require minimal equipment and training, take less time to administer, and are generally safer since less monitoring is required compared to IV (intravenous) infusions.
   
• However, IM injections may result in localized tenderness afterward and produce a slower response than IV delivery, as they have some limitations in delivering fast-acting immunotherapy medications in certain aggressive treatment regimens.
   
• Further, the subcutaneous segment was valued at USD 725.8 million in 2025. Medications can be administered under the skin, or subcutaneously, which is a less invasive method in comparison to IV infusion. Subcutaneous administration is generally used for some targeted therapies as well as certain supportive therapies such as monoclonal antibodies and growth factors.
   
• This method is used as it is both time-saving and cost-effective for infusions, and patients are usually comfortable, which is leading to its growing popularity in outpatient cancer care where efficiency is a focus.
   
• In addition, there is a lower possibility of infection with the use of a subcutaneous administration device compared with an intravenous (IV) line, as it uses less equipment.
   

Looking for region specific data?

Download Free PDF

North America Outpatient Oncology Infusion Market
 

North America market accounted for majority share of 43.1% in 2025 in the global market and is anticipated to show notable growth over the forecast period.
 

• North America accounted for the majority share of the market, benefitting from developed healthcare systems with a large number of people living with cancer and a high rate of adoption for innovative infusion technology.
   
• In addition, patients in the region have comprehensive insurance coverage and are also witnessing growing adoption of value-based care, both of which enable patients to receive outpatient cancer treatment at a more affordable rate than in the acute-care setting.
   
• Various outpatient oncology infusion practices utilize smart infusion pumps and electronic health records (EHR) systems, which increase patient safety and improve operational efficiency.
   
• Major oncology centers support accelerated technological innovation by allowing manufacturers to test their devices in real-world clinical settings. The growth of the market is also being driven by patient demand for convenient access and shorter hospital inpatient stays.
   
• Furthermore, support from regulatory bodies for cancer treatments and the rising adoption of targeted therapies and immunotherapies, coupled with increasing numbers of patients receiving outpatient treatment, have established North America as a leading market.
   

The U.S. outpatient oncology infusion market was valued at USD 860 million and USD 950 million in 2022 and 2023, respectively. In 2025 the market size was valued at USD 1.14 billion from USD 1.04 billion in 2024. Rising focus on value-based reimbursement models in the country is projected to fuel market growth.
 

• The U.S. market growth is anticipated to be driven by the high incidence rate of cancer and a well-developed outpatient infusion service infrastructure, among other factors. For example, as per the data reported in the CDC's U.S. Cancer Statistics report, more than 36.7 million new cancer cases were recorded in the U.S. between 2003 and 2022.
   
• With strong reimbursement policies and governmental support for increased awareness and early detection of cancer, the demand for these types of services is witnessing consistent growth. The adoption of smart pumps and remote monitoring has improved patient safety and increased efficiency within infusion services.
   
• In addition, partnerships between healthcare providers and device manufacturing companies are expanding the reach of infusion services.
   
• Moreover, support for patient preferences for convenience and innovative treatment options, such as immunotherapy, continues to create robust growth in the U.S. market.
   

Europe Outpatient Oncology Infusion Market
 

Europe accounted for a significant share of the global market and was valued at USD 894.3 million in 2025.
 

• The European market continues to develop steadily owing to universal health care systems in regional countries and the adoption of innovative technology. Countries focus on both cost containment and patient-centered care, making outpatient settings an attractive option.
   
• Surging incidence rates of cancer, combined with supportive government incentives for early detection, increases the demand for infusion services.
   
• The use of digital health tools and smart infusion pumps is gaining momentum, leading to increased safety and accuracy in treatment. In addition, the growing number of biosimilar medications available to patients has made treatment more affordable and accessible.
   
• Furthermore, partnerships between hospitals and outpatient centers improve service delivery. With a commitment to affordability, innovation, and high quality of care, Europe is positioned as a key region for future growth opportunities.
   

UK held significant share of the European outpatient oncology infusion market, showcasing robust growth potential.
 

• The National Health Service (NHS) is initiating outpatient-based initiatives to reduce the burden on hospitals and decrease hospital costs, shaping the UK infusion market. The rising incidence of cancer cases and increased utilization of early detection services result in greater demand for infusion services.
   
• The introduction of smart pumps with integrated digital monitoring tools has created a rapid increase in safety and efficiency within the infusion market. In addition, the use of biosimilars is anticipated to significantly contribute to lowering treatment costs within the parameters set forth by the NHS cost control initiatives.
   
• Further, the convenience of outpatient-based care with a reduced time frame for treatment is expected to remain an attractive option for patients.
   

Asia Pacific Outpatient Oncology Infusion Market
 

The Asia Pacific market accounted for a substantial share of the market and was valued at USD 558.4 million in 2025.
 

• The Asia-Pacific region is witnessing an increase in growth due to a combination of numerous factors, such as higher cancer diagnosis rates, improving healthcare systems, and growing knowledge and awareness about the benefits of outpatient treatments.
   
• Countries such as India, Japan, South Korea, and Australia are investing substantially in the development of infusion centers, which are expected to cater to the need for increased treatment options for patients with various cancers.
   
• Additionally, the adoption of advanced technologies, such as the use of smart infusion pumps and telehealth services, is also playing a key role in propelling regional growth.
   
• Further, an increase in the number of government-funded cancer screening programs and efforts toward making treatments more affordable are anticipated to continue to support the penetration of infusion treatment services across the regional market.
   
• Furthermore, urbanization and changes in lifestyle also contribute to increasing rates of cancer, thus projected to fuel the growth of outpatient infusion centers in the coming years.
   

China outpatient oncology infusion market is estimated to grow with a robust CAGR, in the Asia Pacific market.
 

• China’s market is expanding rapidly as a result of increased cancer rates and growing government initiatives to enhance the accessibility of healthcare across the country. Both state-owned and privately funded oncology centers have made significant investments in modern infusion technology and in expanding the number of large-scale oncology centers in the country.
   
• In addition, the recent approvals and market entry of a growing number of biosimilar medications have improved patient access to a wide range of treatments because of reduced therapy costs. This trend is further supported by increased public health awareness regarding the benefits of early diagnosis and treatment of cancer.
   
• Further, collaborative partnerships between local providers and global medical device manufacturers are also driving technological innovation and expanding access to advanced infusion technologies.
   

Latin America Outpatient Oncology Infusion Market
 

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.
 

• Brazil’s market is growing steadily, driven by rising cancer prevalence and government initiatives for early detection. Urban areas lead due to better infrastructure and skilled professionals, while rural regions are witnessing growth owing to increasing healthcare spending.
   
• Private settings are leading to the implementation of smart infusion pumps and infection-control devices, while the public healthcare sector focuses on expanding basic outpatient services.
   
• Moreover, increasing patient preference for convenience and reduced hospital stays further supports market growth. Strategic collaborations between providers and device manufacturers are helping bridge service gaps and improve care delivery.
   

Middle East and Africa Outpatient Oncology Infusion Market
 

Saudi Arabia market to experience substantial growth in the Middle East and Africa market in 2025.
 

• Saudi Arabia’s market expansion is fueled by Vision 2030 healthcare reforms, emphasizing modernization and advanced cancer care. Significant investments in oncology centers and outpatient facilities are accelerating the adoption of infusion services.
   
• Smart infusion pumps, closed-system connectors, and digital monitoring tools are increasingly being integrated to enhance safety and efficiency. Public awareness campaigns and screening programs drive early diagnosis, boosting outpatient treatment demand.
   
• Further, the growing private healthcare sector and partnerships with global device manufacturers improve technology availability. Owing to these developments, Saudi Arabia is emerging as a regional hub for advanced outpatient oncology care.
   

Outpatient Oncology Infusion Market Share

The outpatient infusion market for oncology has a high degree of competition due to the developments in technology, safety, and cost-effectiveness. This space is dominated by major medical device manufacturers, including Becton, Dickinson and Company, Baxter International, B. Braun, Fresenius, and ICU Medical, who have a significant presence in infusion systems with extensive distribution networks. These manufacturers offer smart infusion pumps with automated dosing, error notifications, and EHR integration to improve patient safety and simplify workflow.
 

With these competitive offerings, product differentiation remains an important factor, with manufacturers investing in developing products such as needleless connectors, closed-system drug-transfer devices, and other technologies that help prevent infection and comply with federal regulations.
 

The majority of these manufacturers work in collaboration with oncology clinics and outpatient treatment centers to provide customized solutions and service models. Emerging companies are developing digital health and remote monitoring platforms as a means to compete with well-established players. Whereas major industry players are focusing on acquiring other companies to increase their product lines and market size.
 

Additionally, due to the ongoing pressure from the high prices associated with oncology drugs, manufacturers are developing solutions aligned with value-based pricing and have also started to expand their oncology product portfolios with biosimilars.
 

Furthermore, the competition for innovation, interoperability, and affordability among companies is based on providing connected, patient-centered infusion systems that support the outpatient health care model and enable more patients to receive cancer treatment globally.
 

Outpatient Oncology Infusion Market Companies

Few of the prominent players operating in the global outpatient oncology infusion industry include:
 

• B. Braun
• Baxter
• Becton, Dickinson and Company
• Fresenius Kabi
• ICU Medical
• IRADIMED
• Medtronic
• Micrel
• MOOG
• NIPRO
• Penlon
• Teleflex
• Terumo
  
   
• Becton, Dickinson and Company

BD focuses on expanding smart infusion technologies, integrating connectivity with EHR systems, and enhancing patient safety through closed-system devices. Strategic partnerships and global distribution strengthen its position in markets.
 

• Baxter

Baxter emphasizes interoperability of infusion pumps, cybersecurity, and service-based models. It invests in digital health integration, emerging-market expansion, and collaborative solutions with providers to deliver cost-effective outpatient oncology care.
 

• ICU Medical

ICU Medical strengthens its portfolio of high-precision infusion pumps and needleless connectors. It invests in smart pump software, interoperability, and partnerships with cancer centers to standardize safe outpatient workflows.
 

Outpatient Oncology Infusion Industry News:

• In May 2025, Penlon launched a new infusion system range, including the HP TCi Syringe Pump, SYS-56, and SYS-70 that provides clinicians with smarter, safer, and more simplified control over infusion in various clinical situations. The advanced features of the Penlon HP TCi Syringe Pump provide efficient, accurate, and reliable intravenous anesthesia delivery. This development is projected to substantially expand the company's product range and sales prospects in the industry.
   
• In April 2025, ICU Medical Inc. announced 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Plum Solo precision IV pump. It has also received clearance for updated versions of the Plum Duo precision IV pump and LifeShield infusion safety software. This product launch is expected to improve the company's position in the industry.
   
• In September 2024, BD announced new data that shows some of the BD needle-free connectors demonstrated decreased risk for central venous catheter intraluminal blood occlusions (CVC-IBO) and central line-associated bloodstream infections (CLABSI). This improved product range may enable the company to improve its brand image and further consolidate its market position.
   

The global outpatient oncology infusion market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in (USD Million) from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Infusion pumps
• Intravenous sets
• IV cannulas
• Needleless connectors

Market, By Application

• Lung cancer
• Liver cancer
• Breast cancer
• Prostate cancer
• Other cancers

Market, By Therapy

• Chemotherapy
• Targeted therapy
• Immunotherapy
• Hormonal therapy

Market, By Mode

• Intramuscular (IM)
• Intravenous (IV)
• Subcutaneous
• Other modes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Nigeria
  • Egypt